Bone Tumor Ablation Devices Market Size & Forecast 2033

Technological Advancements in Image-Guided Ablation Procedures to Drive Global Bone Tumor Ablation Devices Market to USD 219.3 Mn by 2033 at 10.2% CAGR – Coherent Market Insights

Market Driver

Rising Burden of Metastatic Bone Disease and Demand for Minimally Invasive Pain Management

The increasing prevalence of advanced cancers that spread to the bones is a major driver of the Global Bone Tumor Ablation Devices Market. Bone is one of the most common sites of cancer metastasis, particularly for breast, prostate, lung, kidney, and thyroid cancers. Bone metastases frequently cause severe pain, fractures, and reduced mobility, increasing demand for image-guided radiofrequency, microwave, and cryoablation procedures that provide targeted treatment with less morbidity than open surgery.

For instance, on July 3, 2026, the World Health Organization reported that cancer accounted for nearly 10 million deaths globally in 2024 and stated that widespread metastases are the primary cause of cancer-related mortality. This substantial advanced-cancer burden supports growing demand for technologies that manage metastatic bone lesions and associated pain.

Clinical adoption is also supported by the SPARTA study, published on March 31, 2026, which found that radiofrequency ablation provided rapid and substantial pain relief within one month and improved quality of life among patients with bone metastases. These outcomes strengthen the clinical case for adopting minimally invasive bone tumor ablation devices in hospitals and specialized cancer centres. (Source: WHO)

Market Opportunity

Expansion of Non-invasive and Image-guided Ablation for Bone Metastases

The expanding use of non-invasive and minimally invasive ablation technologies for managing painful bone metastases presents a significant opportunity for the Global Bone Tumor Ablation Devices Market. Technologies such as radiofrequency ablation, cryoablation, microwave ablation, and MRI-guided focused ultrasound can provide targeted pain relief while reducing the need for open surgery. This creates opportunities for manufacturers to develop advanced ablation generators, precision probes, temperature-monitoring systems, treatment-planning software, and integrated image-guided platforms.

For instance, in May 2026, the Focused Ultrasound Foundation reported that focused ultrasound was approved for treating painful bone metastases in the U.S. and several international markets. The technology offers a non-invasive and radiation-free treatment option, can provide rapid pain relief, and is covered by most major U.S. health insurers, with reimbursement also available in Germany and Italy. The Foundation also cited a 2026 expert consensus on MRI-guided focused ultrasound surgery for painful bone metastases, indicating growing clinical standardization and adoption. The commercial opportunity is further supported by the 2026 SPARTA study, which found that radiofrequency ablation delivered rapid and substantial pain relief within one month and improved quality of life among patients with bone metastases. Moreover, the World Health Organization reported in July 2026 that cancer accounted for nearly 10 million deaths globally in 2024 and that widespread metastases remain the primary cause of cancer-related mortality, highlighting the substantial potential patient population requiring effective metastatic disease management.

Market Trends

Microwave Ablation Emerging as an Alternative to Radiofrequency Ablation

Although radiofrequency ablation remains the established treatment for osteoid osteoma, microwave ablation is gaining attention because it can produce faster heating, broader ablation zones, reduced heat-sink effects, and more homogeneous tissue destruction. For instance, a June 2026 study involving 35 osteoid osteoma patients found that microwave ablation significantly reduced pain in 34 patients, representing 97.1% of the study group. Average pain scores decreased from 7.4 before treatment to 1.9 after treatment, while the average hospital stay was three days.

Expanding Use of Cryoablation for Bone Metastases

Cryoablation is increasingly being used for painful skeletal metastases, oligometastatic bone disease, benign tumors, and recurrent or inoperable musculoskeletal tumors. Its ability to visualize the developing ice ball through imaging enables physicians to control the ablation margin and protect surrounding nerves and healthy tissues. A state-of-the-art review published in February 2026 identified image-guided percutaneous cryoablation as an increasingly important treatment for osteoid osteoma, painful skeletal metastases, oligometastatic disease, recurrent sarcomas, and other painful benign bone tumors.

Growing Focus on Pain Palliation and Quality-of-Life Improvement

Bone tumor ablation devices are increasingly positioned not only for local tumor destruction but also for rapid pain management among patients with metastatic cancer who have failed radiotherapy, reached radiation limits, or are unsuitable for major surgery. A May 2026 study on percutaneous cryoablation for sternal bone metastases concluded that the procedure was safe and effective for pain palliation and warranted further clinical evaluation. Another February 2026 study reported short-term pain reduction among bone-metastasis patients treated with a co-ablation system, without ablation-related adverse events.

Integration of Ablation with Cementoplasty and Screw Fixation

For weight-bearing or structurally weakened bones, ablation is increasingly being combined with cementoplasty and percutaneous screw fixation. This combined approach simultaneously destroys tumor tissue, improves mechanical stability, relieves pain, and enables earlier patient mobility. A study published online in May 2026 reported 100% technical success for combined cryoablation, screw fixation, and cementoplasty in 17 patients with painful pelvic bone metastases. Approximately 76.5% of patients were able to stand within 24 hours, with significant improvements in pain and quality of life after one month.

Development of Hybrid and Multi-Energy Ablation Systems

Manufacturers and researchers are exploring systems that combine different energy mechanisms, such as hyperthermic ablation and cryoablation. These hybrid technologies are intended to create more controlled ablation zones, improve pain relief, and overcome limitations associated with a single thermal modality. For instance, a February 2026 exploratory study assessed a co-ablation system combining hyperthermic and cryogenic mechanisms for patients with bone metastases. The system was found feasible and was associated with short-term pain reduction, although larger prospective studies are still required.

Greater Emphasis on Standardization and Radiation-Dose Reduction

As CT-guided ablation expands among pediatric and younger patients, hospitals are focusing on procedure standardization, dose benchmarks, real-time temperature monitoring, and navigation-assisted probe positioning. This is creating opportunities for low-dose CT protocols, cone-beam CT, robotic navigation, temperature sensors, and treatment-planning software.

Global Bone Tumor Ablation Devices Market, by Technology (Radiofrequency Ablation, Microwave Ablation, Cryoablation, and Others), by Indication (Osteosarcoma, Chondrosarcoma, Ewing’s Sarcoma, Metastatic Bone Cancer, and Others), by End user (Hospitals, Ambulatory Surgical Centers, and Specialty Clinics), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 111.0 Mn in 2026 and is expected to exhibit a CAGR of 10.2% during the forecast period (2026-2033), as highlighted in a new report published by Coherent Market Insights.

To know the latest trends and insights related to bone tumor ablation devices market, click the link below:

https://www.coherentmarketinsights.com/market-insight/bone-tumor-ablation-devices-market-4319

Key Takeaways of the Bone Tumor Ablation Devices Market

The bone tumor ablation devices market is expected to exhibit a CAGR of 10.2% during the forecast period (2026–2033), owing to the increasing number of product approvals and launches by key players.
Based on technology, the radiofrequency ablation segment is anticipated to dominate the Global Bone Tumor Ablation Devices Market with a 42.5% share in 2026. This leadership is attributed to its established clinical use, minimally invasive nature, procedural precision, and effectiveness in treating osteoid osteoma and painful metastatic bone lesions. In 2026, the SPARTA study evaluated the safety and efficacy of radiofrequency ablation for the palliative treatment of bone metastases, while another multi-institutional study examined CT-guided radiofrequency ablation for osteoid osteoma, demonstrating its continued adoption across benign and metastatic bone tumors.
Based on indication, the metastatic bone cancer segment is estimated to account for the largest market share of 48.0% in 2026. The segment’s dominance is driven by the high burden of secondary bone tumors and the increasing use of thermal ablation for pain palliation, local tumor control, and improved patient mobility. In its July 2026 cancer fact sheet, the World Health Organization reported nearly 10 million cancer deaths globally in 2024 and clarified that widespread metastases are the primary cause of cancer-related mortality. Additionally, a 2026 British Journal of Radiology review highlighted the growing use of radiofrequency ablation, microwave ablation, cryoablation, and focused ultrasound for metastatic bone disease. (Source: WHO)
Based on end user, hospitals are projected to lead the Global Bone Tumor Ablation Devices Market with a 64.0% share in 2026. Hospitals are the primary treatment settings due to their access to CT, MRI, PET, and other advanced imaging systems, multidisciplinary oncology teams, interventional radiologists, anesthesia support, and facilities required for complex ablation procedures. In April 2026, the American Hospital Association emphasized the central role of radiology in diagnosis, treatment monitoring, and minimally invasive procedures. Cleveland Clinic’s 2026 bone tumor treatment services also include advanced imaging, cryotherapy, and radiofrequency ablation, illustrating the concentration of these procedures in specialized hospitals. (Source AHA)
Major players operating in the bone tumor ablation devices market include Medtronic Plc., Merit Medical Systems Inc., MedWaves Inc., AngioDynamics Inc., Olympus Corporation, Varian Medical Systems, Inc., Mermaid Medical A/S, RF Medical Co., Ltd., and Misomix Inc.

Key Development

In May 2026, Precision IO Group, a medical device and technology company launched the EPIOS multicentre U.S. clinical study to evaluate the safety and performance of its Epione robotic platform for treating bone tumors and metastases. The first patient was treated in Miami on April 28, 2026. The study aims to support expanded U.S. regulatory approvals for robot-assisted, image-guided percutaneous tumor ablation. Epione has been CE-marked for bone indications in Europe since September 2025. (Source: Precision IO Group)
In March 2026, Quantum Surgical, a medical robotics and AI company obtained authorization from Taiwan’s Ministry of Health and Welfare to market and commercialize the Epione robotic platform in Taiwan. The authorization covers tumors and lesions involving abdominal, chest, and musculoskeletal structures, supporting the geographic expansion of robotic-assisted, minimally invasive tumor ablation technology. (Source: Quantum Surgical)